BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 6652630)

  • 21. Phase I trial of mitoxantrone by 24-hour continuous infusion.
    Anderson KC; Garnick MB; Meshad MW; Cohen GI; Pegg WJ; Frei E; Israel M; Modest E; Canellos GP
    Cancer Treat Rep; 1983 May; 67(5):435-8. PubMed ID: 6850662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
    Smith DC; Chay CH; Dunn RL; Fardig J; Esper P; Olson K; Pienta KJ
    Cancer; 2003 Jul; 98(2):269-76. PubMed ID: 12872344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial.
    Meluch AA; Greco FA; Morrissey LH; Raefsky EL; Steis RG; Butts JA; Hainsworth JD;
    Cancer; 2003 Nov; 98(10):2192-8. PubMed ID: 14601089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma.
    Vaishampayan U; Glode M; Du W; Kraft A; Hudes G; Wright J; Hussain M
    Clin Cancer Res; 2000 Nov; 6(11):4205-8. PubMed ID: 11106233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma.
    Bhandari MS; Pienta KJ; Fardig J; Olson K; Smith DC
    Cancer; 2006 Apr; 106(8):1715-21. PubMed ID: 16534795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mitoxantrone, vinorelbine and prednisone (MVD) in the treatment of metastatic hormonoresistant prostate cancer--a phase II trial.
    Bernardi D; Talamini R; Zanetti M; Simonelli C; Vaccher E; Spina M; Tirelli U
    Prostate Cancer Prostatic Dis; 2004; 7(1):45-9. PubMed ID: 14999238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer: a Phase II feasibility study conducted by the Hellenic Cooperative Oncology Group.
    Samelis GF; Kalofonos H; Adamou A; Kosmides P; Skarlos D; Aravantinos G; Kiamouris C; Adimchi O; Fountzilas G; Dimopoulos AM
    Urology; 2005 Aug; 66(2):382-5. PubMed ID: 16098366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized Phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer.
    Cabrespine A; Guy L; Khenifar E; Curé H; Fleury J; Penault-Llorca F; Kwiatkowski F; Barthomeuf C; Chollet P; Bay JO
    Urology; 2006 Feb; 67(2):354-9. PubMed ID: 16442593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II trial of mitoxantrone in patients with primary liver cancer.
    Falkson G; Coetzer BJ; Terblanche AP
    Cancer Treat Rep; 1984 Oct; 68(10):1311-2. PubMed ID: 6525607
    [No Abstract]   [Full Text] [Related]  

  • 30. Phase II study of hexamethylmelamine for disseminated prostatic carcinoma.
    Drelichman A; Brownlee R; Al-Sarraf M
    Cancer Clin Trials; 1981; 4(3):309-12. PubMed ID: 6793256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Phase II study of mitoxantrone for acute leukemia].
    Oguma S; Tatsumi Y; Hirayama F; Tani Y; Kubota Y; Kanakura Y; Ueda T; Nakamura H; Shibata H; Masaoka T
    Gan To Kagaku Ryoho; 1984 Mar; 11(3):497-501. PubMed ID: 6703723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer.
    Dexeus F; Logothetis CJ; Samuels ML; Hossan E; von Eschenbach AC
    Cancer Treat Rep; 1985; 69(7-8):885-6. PubMed ID: 4016795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.
    Hussain M; Tangen CM; Lara PN; Vaishampayan UN; Petrylak DP; Colevas AD; Sakr WA; Crawford ED;
    J Clin Oncol; 2005 Dec; 23(34):8724-9. PubMed ID: 16314632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer.
    Chan JS; Beer TM; Quinn DI; Pinski JK; Garzotto M; Sokoloff M; Dehaze DR; Ryan CW
    BJU Int; 2008 Dec; 102(11):1601-6. PubMed ID: 18782306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activity of weekly paclitaxel in advanced hormone-refractory prostate cancer.
    Chiappino I; Destefanis P; Addeo A; Galetto A; Cucchiarale G; Munoz F; Zitella A; Ferrando U; Fontana D; Ricardi U; Tizzani A; Bertetto O
    Am J Clin Oncol; 2007 Jun; 30(3):234-8. PubMed ID: 17551298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.
    Rago RP; Einstein A; Lush R; Beer TM; Ko YJ; Henner WD; Bubley G; Merica EA; Garg V; Ette E; Harding MW; Dalton WS
    Cancer Chemother Pharmacol; 2003 Apr; 51(4):297-305. PubMed ID: 12721757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of platinum sensitivity and resistance by cyclosporin A in refractory ovarian and fallopian tube cancer patients: a phase II study.
    Chambers SK; Davis CA; Schwartz PE; Kohorn EI; Chambers JT
    Clin Cancer Res; 1996 Oct; 2(10):1693-7. PubMed ID: 9816118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Phase II study of mitoxantrone for hematologic malignancies].
    Ueoka H; Ueno K; Yamane T; Toyoda K; Endo H; Nishihara R; Takahashi I; Ohnoshi T; Kitajima K; Kimura I
    Gan To Kagaku Ryoho; 1983 Nov; 10(11):2399-402. PubMed ID: 6639101
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
    Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
    Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.